Ildong’s exclusive distribution of LGLS’s Factive in Korea

Published: 2013-03-19 06:57:00

Updated: 2013-03-19 06:57:00

LG Life Sciences (LGLS) and Ildong Pharmaceutical announced Friday they have concluded an agreement that Ildong will exclusively distribute Factive (gemifloxacin), a synthetic broad-spectrum antibacterial agent for oral administration, in Korea over the next 10 years, while LGLS will focus on overseas markets.

Factive is commonly prescribed to treat certain types of bacterial infections. Sp...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.